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ABSTRACT
Objectives To evaluate synovitis (clinical vs ultrasound 
(US)) to predict structural progression in rheumatoid 
arthritis (RA).
Methods Patients with RA.
Study design Prospective, 2-year follow-up.
Data collected Synovitis (32 joints (2 wrists, 10 
metacarpophalangeal, 10 proximal interphalangeal, 10 
metatarsophalangeal)) at baseline and after 4 months 
of therapy by clinical, US grey scale (GS-US) and power 
doppler (PD-US); x-rays at baseline and at year 2.
Analysis Measures of association (OR) were tested 
between structural deterioration and the presence of 
baseline synovitis, or its persistence, after 4 months of 
therapy using generalised estimating equation analysis.
Results Structural deterioration was observed 
in 9% of the 1888 evaluated joints in 59 patients. 
Baseline synovitis increased the risk of structural 
progression: OR=2.01 (1.36–2.98) p<0.001 versus 
1.61 (1.06–2.45) p=0.026 versus 1.75 (1.18–2.58) 
p=0.005 for the clinical versus US-GS versus US-PD 
evaluation, respectively. In the joints with normal baseline 
examination (clinical or US), an increased probability for 
structural progression in the presence of synovitis for the 
other modality was also observed (OR=2.16 (1.16–4.02) 
p=0.015 and 3.50 (1.77–6.95) p<0.001 for US-GS 
and US-PD and 2.79 (1.35–5.76) p=0.002) for clinical 
examination. Persistent (vs disappearance) synovitis after 
4 months of therapy was also predictive of subsequent 
structural progression.
Conclusions This study confi rms the validity of synovitis 
for predicting subsequent structural deterioration 
irrespective of the modality of examination of joints, but 
also suggests that both clinical and ultrasonographic 
examinations may be relevant to optimally evaluate the 
risk of subsequent structural deterioration.
INTRODUCTION
In rheumatoid arthritis (RA), structural damage is 
associated with irreversible pain and functional 
impairments.1–3 The presence of synovitis (mainly the 
number of swollen joints at physical examination) has 
been recognised as one of the most important predis-
posing factor of subsequent structural damage.4–6
The current objective of RA treatment is to 
improve patient symptoms such as pain, functional 
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impairment and fatigue, and to prevent subsequent 
damage. The intensity of patients’ symptoms is 
correlated with the level of inﬂ ammation, but at a 
lower magnitude than objective signs of inﬂ amma-
tion, such as the number of swollen joints. Such 
a switch in the main aim of the current indication 
of drugs in RA (ie, prevention vs improvement) 
should result/has resulted in changes when initiat-
ing/intensifying disease modifying antirheumatic 
drug therapy in daily practice.7 8 In particular, spe-
ciﬁ c attention should be given to the presence of 
synovitis.
Synovitis is usually evaluated via a physical 
examination.9 During the last decade, ultrasound 
(US) evaluation of synovitis has demonstrated its 
superiority versus physical examination in terms of 
face validity and reliability.10–13 Because the main 
interest of the clinician in evaluating synovitis is 
to understand the level of risk of the patient with 
respect to subsequent structural deterioration, spe-
ciﬁ c attention has to be given to the capacity for 
US evaluation of synovitis to predict subsequent 
progression of structural damage.
Several longitudinal studies have demonstrated a 
link between the presence of synovitis detected by 
US at a certain point in time and subsequent struc-
tural deterioration. However, most of these studies 
have considered these two variables (eg, synovitis 
and structural damage) at the patient level, evaluat-
ing the correlation between the number of synovitic 
joints at a certain time-point and the subsequent 
structural deterioration using a radiological scor-
ing system including multiple and often different 
joints, such as those included in the modiﬁ ed Sharp 
Score,14–18 and only a few of them have evaluated 
this correlation at the level of the joints.19 20
Most of these studies have not compared the 
magnitude of this link or its predictive validity with 
regard to the particular modality of evaluation of 
joints (eg, clinical examination vs US modality). 
Moreover, most of these studies have not evalu-
ated whether the disappearance of synovitis after 
treatment in the short term prevents subsequent 
structural deterioration.
This context prompted us to conduct a 2-year 
longitudinal study aimed at evaluating the capac-
ity of synovitis to predict subsequent radiological 
damage with respect to the modality of examina-
tion of joints in patients with RA.
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PATIENTS-METHODS
Study design
The study comprised two phases: the ﬁ rst was a prospec-
tive, multicentre, international 4-month-duration follow-up 
of patients with RA requiring a tumour necrosis factor (TNF)-
blocker according to the opinion of their treating rheumatolo-
gist. The results of this study aimed at evaluating psychometric 
properties (including reliability, external validity, sensitivity to 
change and discriminant capacity) of different synovitis scor-
ing systems has been previously reported.21 The second part of 
the study consisted in a radiological evaluation (hands and feet) 
2 years after the inclusion of the patients in the study.
This study was approved by the appropriate ethical commit-
tees. All patients gave their written informed consent before 
enrolling for the study.
Patients
Adult patients fulﬁ lling the 1987 American College of 
Rheumatology criteria for RA22 were eligible for the study if, in 
the opinion of the investigators, he/she required a TNF-blocker 
therapy. The minimum level of disease activity was deﬁ ned by 
the number of swollen joints at physical examination ≥6.
Centres
To be eligible, the centres had to fulﬁ l the following criteria: 
(1) a sonographer (either a radiologist or a rheumatologist) with 
experience (at least 70 different examinations) in evaluating 
synovitis; (2) a clinician (either a rheumatologist or a research 
nurse) with experience in clinical metrology in RA; (3) inde-
pendent examination of synovitis (eg, for a single patient, the 
sonographer could not have access to the results of the clini-
cal examination and vice versa); (4) monitoring of the patient 
during the 4-month period of study by the same investigators 
(eg, a single sonographer and a single clinician for each individ-
ual patient over the 4-month period of the study).
Collected data
Thirty-two joints were systematically evaluated (clinical and 
ultrasonographic evaluation before (baseline) and after 4 months 
of TNF-blockers therapy, radiological evaluation at baseline, and 
after 2 years of follow-up).
The evaluated joints included the metacarpophalangeal (MCP) 
(×10), the proximal interphalangeal (PIP) (×10), the wrists (×2) 
and the metatarsophalangeal (MTP) (×10) joints. For each joint, 
the clinical scoring system was a semiquantitative variable (eg, 
0=deﬁ nitely no synovitis, 1=doubtful, 2=yes moderate, 3=yes 
obvious and important).
The US evaluation was performed in a darkened room. 
Systematic multiplanar grey-scale (GS) and power dop-
pler (PD) examinations were carried out with commercially 
available real-time scanners (eg, ESAOTE Technos MPX, 
ESAOTE MyLab, TOSHIBA APLIO, PHILIPS HD11, BK Mini 
Focus) using multifrequency linear transducers (7–12 MHz). 
Ultrasonography scanning techniques, GS and PD machine set-
tings, and deﬁ nitions of abnormality were standardised among 
investigators prior to the study during a 1.5-day meeting.23 
It has to be noted that the ﬁ ngers were evaluated only at the 
dorsal side. The US scanning scoring method has been described 
previously.24–29 Synovitis was deﬁ ned according to the Outcome 
Measures in Rheumatology Clinical Trials published deﬁ ni-
tions.26 27 30 31 Both a GS and a PD examination were recorded 
for each joint.
GS synovitis scoring was evaluated using a 4-grade scale 
from 0 to 3 with the following subjective deﬁ nitions for each 
category:
▶ grade 0 = absence of synovial thickening;
▶ grade 1 = mild synovial thickening;
▶ grade 2 = moderate synovial thickening;
▶ grade 3 = marked synovial thickening.
PD synovitis scoring was evaluated also using a 4-grade scale 
from 0 to 3 with the following deﬁ nition for each category:
▶ grade 0 = absence of signal, no intra-articular ﬂ ow;
▶ grade 1 = mild, one or two vessels signal (including one con-
ﬂ uent vessel) for small joints and two to three signals for 
large joints (including two conﬂ uent vessels);
▶ grade 2 = moderate conﬂ uent vessels (>grade 1) and less than 
50% of normal area;
▶ grade 3 = marked vessels’ signals in more than half the syno-
vial area.
The radiological evaluation (plain x-rays of hands, wrists and 
feet) was performed by a single experienced reader (VD),32–36 
aware of the chronologies of the ﬁ lms but unaware of the clini-
cal and US ﬁ ndings.
For each of the 32 joints, and for each-time point (eg, baseline 
and 24 months), the scoring system for both erosion and joint 
space narrowing (JSN) was a semiquantitative variable (scored 
0=absent, 1=doubtful, 2=obvious but moderate, 3=obvious and 
important). Moreover, there was also an evaluation concerning 
the global assessment using a binary variable for each joint and 
for both erosion and joint space narrowing (scored 0=no change, 
1=worsening).
Statistical analysis
The statistical analysis was performed on patients with a com-
plete dataset (clinical and US evaluation at baseline, and after 
4 months of follow-up and radiological evaluation at baseline, 
and after 2 years of follow-up).
The ﬁ rst step of the statistical analysis consisted in the tabu-
lation of the main baseline characteristics of the patients and 
the evaluated joints using mean and SD for the continuous, and 
percentages for dichotomous variables.
The probability of structural deterioration with regard to the 
speciﬁ c joint region was estimated by calculating the percent-
age of joints with radiological progression, deﬁ ned by either the 
occurrence or worsening in either erosion or joint space narrow-
ing score after the 2-year follow-up period in each of the fol-
lowing four anatomical regions (wrists, MCP, PIP, MTP) without 
performing any statistical test.
The probability of structural deterioration with regard to the 
presence of synovitis at baseline was estimated by comparing 
the percentage of joints with radiological progression deﬁ ned by 
either occurrence or worsening in either erosion or JSN in the 
joints with or without synovitis at baseline for the three differ-
ent baseline synovitis evaluations (clinical, US-GS and US-PD).
The risk of progression with respect to the presence of syno-
vitis at baseline was estimated by calculating the OR with its 
95% CI. These measures of association were tested using gener-
alised estimating equation analysis adjusting for within-patient 
correlation, and also other factors (age, gender, disease duration, 
baseline tender joint count, swollen joint count, ESR joint locali-
sation (eg, PIP, MCP, wrists, MTP) and baseline structural dam-
age). Such probability of structural deterioration with regard to 
the presence of synovitis at baseline either at physical examina-
tion, US-GS or US-PD evaluation was initially calculated in the 
whole population.
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The second step of the statistical analysis was focused on the 
subgroup of joints considered normal by the physicians (one 
analysis) or the US (another analysis) at baseline, calculating the 
predictive validity of US evaluation in the group of joints with 
normal baseline physical examination (one analysis) and also cal-
culating the predictive validity of clinical evaluation in the group 
of joints with normal US (GS and PD) baseline examination.
The third step tried to check whether a positive short-term 
treatment effect on synovitis permits to prevent a subsequent 
structural deterioration. For this purpose, we considered as 
‘baseline abnormal joint’, joints with a clinical or US score either 
>0 or >1 (eg, considering as ‘normal’ the joints with a ‘doubtful’ 
clinical examination or only with ‘mild synovial thickening’ at 
US-GS examination, or only ‘mild’ US-PF ﬁ ndings). Thereafter, 
the joints were split into two categories with regard to the 
normalisation of the examination after 4 months of anti-TNF 
therapies, calculating the probability of observing radiological 
progression after 2 years with respect to this treatment effect.
RESULTS
Patients and study course
Of the 77 recruited patients in the ﬁ rst part of the study, one had 
no baseline US examination and was therefore excluded from 
this study. Seventeen additional patients did not return for the 
2-year follow-up visit resulting in 59 patients with a complete 
dataset.
The main characteristics of the patients (data provided are 
either % or mean±SD) (age: 56±12 years old, gender: 81% 
female, body mass index: 25±5 kg/m2) of their disease (dis-
ease duration: 10±8 years, rheumatoid factor positivity: 73%, 
history of surgery for RA (eg, articular prosthesis, arthrodesis 
or resection) 24%) and of their treatment (median number of 
previous disease modifying antirheumatic drugs: 3.0, history 
of TNF blockers: 32%) were similar to the whole population 
of 77 screened patients (data not shown). The disease activity 
evaluated by the disease activity score in 28 joints was quite 
high at entry (5.1±1.3) and dropped to 3.4±1.3) after 4 months 
of anti-TNF therapy (etanercept, n=34; adalimumab, n=23, inf-
liximab, n=2). The same improvement was observed in terms 
of functional disability with a health assessment questionnaire 
score decreasing from 1.4±0.7 to 1.0±0.7 between baseline and 
the 4-month follow-up visit, respectively.
Table 1 summarises the main characteristics of the 1888 eval-
uated joints (eg, 32 joints in 59 patients) conﬁ rming a higher sen-
sitivity of US in detecting synovitis, particularly in the feet.
Table 1 Baseline characteristics of the 1888 evaluated joints of the 59 
studied patients with rheumatoid arthritis 
Characteristics
Joints
Wrists MCP PIP MTP Total
Number 118 590 590 590 1888
Clinical synovitis
0 = absent 19.7* 49.0 56.8 77.1 58.4
1 = doubtful 23.1 13.3 11.7 12.2 13.1
2 = present, moderate 38.5 23.1 21.0 8.0 18.7
3 = present, important 18.8 14.6 10.5 2.7 9.9
US grey-scale synovitis†
Grade 0 17.9 49.5 62.5 44.3 50.0
Grade 1 35.0 15.1 11.4 26.2 18.6
Grade 2 27.4 13.6 10.8 15.3 14.1
Grade 3 19.7 21.8 15.3 14.2 17.3
US Power Doppler†
Grade 0 40.2 71.6 82.5 78.0 75.1
Grade 1 17.9 9.2 8.5 9.3 9.5
Grade 2 32.5 13.9 4.9 9.3 10.8
Grade 3 9.4 5.3 4.1 3.4 4.6
*numbers provided are the percentage of joints in a specifi c category.
†see Methods section for detailed description of the ultrasonographic grading systems.
MCP, metacarpophalangeal; MTP, metatarsophalangeal; PIP, proximal interphalangeal; 
US, ultrasound.
Figure 1 Probability of radiological progression after a 2-year 
follow-up period with regard to the presence of baseline synovitis 
defi ned by either clinical or ultrasonographic examination. *Radiological 
progression = occurrence or worsening of erosion or joint space 
narrowing. **Score of ‘clinical’ synovitis (0 = no synovitis; 1 = 
doubtful synovitis; 2 = obvious and moderate synovitis; 3 = obvious 
and important synovitis. ***Score of ultrasonography grey-scale 
evaluation: 0 = absence of synovial thickening; 1 = mild synovial 
thickening; 2 = moderate synovial thickening; 3 = marked synovial 
thickening. ****Score of ultrasonographic Power Doppler evaluation: 
0 = absence of signal, no intra-articular fl ow; 1 = mild, one or two 
vessels’ signals (including one confl uent vessel) for small joints and two 
to three signals for large joints (including two confl uent vessels); 2 = 
moderate confl uent vessels (>grade 1) and less than 50% of normal 
area; 3 = marked vessels’ signals in more than half the synovial area.
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The probability of observing radiological progression deﬁ ned 
by the occurrence of the worsening in either erosion or joint 
space narrowing was quite low (eg, 9% of the 1888 evaluated 
joints). Such probability was higher for the wrists (16.2%) and 
MTP joints (11%) than for the other joints (7.0% and 7.5% for 
the MCP and PIP, respectively).
Correlations between baseline synovitis evaluations and radi-
ological structural deterioration after 2 years of follow-up.
The online supplementary tables 1, 2 and 3 provide the data 
observed from the different analyses with respect to the deﬁ ni-
tion of radiological structural deterioration (considering either the 
changes in radiological erosion, radiological JSN) and also with 
respect to the individual synovitis scoring systems at baseline.
The data observed when deﬁ ning radiological progression by 
the occurrence or the worsening in either erosion or JSN, and 
when deﬁ ning the presence of synovitis at baseline by a score 
of at least 1 on clinical or US scales are summarised in ﬁ gure 1. 
Such results were still observed when excluding MTP 1 and 2 of 
the analyses (data not shown).
Regardless of what technique was used to assess synovitis, 
the presence of synovitis was predictive of subsequent struc-
tural deterioration. However, the observed OR with the 95% CI 
did not demonstrate a statistically signiﬁ cant difference in the 
magnitude of this link between the different methods of syno-
vitis evaluation.
With respect to the subgroup analyses: the ﬁ rst subgroup of 
interest was deﬁ ned by the 1101 joints the investigators con-
sidered as normal at physical examination (23 wrists, 288 MCP, 
335PIP and 455 MTP). Structural deterioration deﬁ ned by either 
the occurrence or the worsening in either erosion or joint space 
narrowing was observed in 6.6% of the joints, but more fre-
quently in the presence of any synovitis (grade >0) detected by 
US, either by GS (10.5%) or by PD (15.6%) (ﬁ gure 2A) with OR 
of 2.16 (1.16–4.02), p=0.015 and of 3.50 (1.77–6.95), p<0.001, 
respectively.
The second subgroup of interest was deﬁ ned by the 938 joints 
that US considered as normal according to both GS and PD 
techniques (21 wrists, 290 MCP, 369 PIP, 258 MTP). Structural 
deterioration deﬁ ned by either the occurrence or the worsen-
ing in either erosion or JSN was observed in 5.9% of the joints, 
but more frequently in the presence of any synovitis (grade >0) 
detected by physical examination (9.9%) with an OR of 2.79 
(1.35–5.76), p=0.005 (ﬁ gure 2B).
Finally, we also evaluated the probability of observing radio-
logical progression after 2 years of follow-up with respect to 
the persistence of synovitis after 4 months of therapy. The two 
analyses conducted (the one conducted in the joints deﬁ ned as 
abnormal by a score above 0 and the one by a score above 1), 
showed a trend or statistical signiﬁ cance suggesting more fre-
quent structural progression in case of persistent synovitis. In 
the analysis considering an abnormal baseline joint as a joint 
with a score of at least 1 (784, 939 and 468 joints at clinical, 
US-GS and US-PD evaluations, respectively), radiological pro-
gression was observed more frequently in the case of persistent 
synovitis (16.6% vs 8.9% for clinical evaluation (OR=1.26 (0.79–
2.02), p=0.336; 17.1% vs 5.9% for US-GS evaluation (OR=2.41 
(1.24–4.67), p=0.010) and 20.7% versus 11.9% for US-PD evalu-
ation (OR=1.63 (0.75–3.57), p=0.218 in joints with, versus with-
out persistent synovitis, respectively. These ﬁ ndings were even 
more pronounced when considering abnormal baseline joints by 
a score of at least two (ﬁ gure 3) (538, 589 and 289 joints at clini-
cal, US-GS and US-PD evaluations, respectively). Radiological 
progression was observed more frequently in case of persistent 
synovitis after 4 months (15.7% vs 7.5% for clinical evaluation 
(OR=1.70 (0.93–3.12), p=0.086); 19.3% versus 6.5% for US-GS 
evaluation (OR=3.14 (1.50–6.55), p=0.002) and 21.1% vs 8.0% 
Figure 2 Probability of radiological progression after a 2-year follow-up period with regard to the presence of synovitis at baseline and the modality 
of joint examination in two different groups of joints. *Radiological progression = occurrence or worsening of erosion or joint space narrowing. 
**Score of ‘clinical’ synovitis (0 = no synovitis; 1 = doubtful synovitis; 2 = obvious and moderate synovitis; 3 = obvious and important synovitis. 
***Score of ultrasonography grey-scale evaluation: 0 = absence of synovial thickening; 1 = mild synovial thickening; 2 = moderate synovial 
thickening; 3 = marked synovial thickening. ****Score of ultrasonographic Power Doppler evaluation: 0 = absence of signal, no intra-articular fl ow; 
1 = mild, one or two vessels’ signals (including one confl uent vessel) for small joints and two to three signals for large joints (including two confl uent 
vessels); 2 = moderate confl uent vessels (>grade 1) and less than 50% of normal area; 3 = marked vessels’ signals in more than half the synovial 
area.
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for US-PD evaluation (OR=2.79 (1.19–6.56), p=0.019) in joints 
with, versus without persistent synovitis, respectively.
DISCUSSION
This study conﬁ rms the ability of synovitis to predict subsequent 
structural deterioration in patients with RA. The data observed 
in the whole set of joints suggest that such predictive validity is 
of similar magnitude whatever the modality of the joint exami-
nation (ie, whether clinical or US evaluation). The data observed 
in the subgroups of joints (with normal clinical or US baseline 
examination) suggest that both clinical and US evaluations are 
relevant to optimally evaluate the risk of subsequent structural 
deterioration. Finally, these data emphasise the importance of 
persistent synovitis since the probability of a 2-year structural 
progression was higher in cases of persistent synovitis after 
4 months of anti-TNF therapy.
All the investigators involved in the collection of synovitis 
outcome measures were experienced in their particular areas. 
Moreover, all the investigators participated at a 1-day training 
session on assessment of clinical and US synovitis outcome 
measures.37 The information given above can be seen as the 
strength of this study but may also reduce the generalisation to 
other sets of investigators.
The ﬁ ndings observed in our study are in accordance with 
previous studies showing a link between the presence of syno-
vitis at a single point in time, and a subsequent structural dete-
rioration. Most of the studies evaluating the predictive validity 
of synovitis detected by US have considered the two variables 
(synovitis and radiological changes) at the patient level by con-
sidering, for example, the total number of joints with synovi-
tis and a summed radiological scoring system.14–16 18 We have 
focused our study by evaluating the risk of structural progres-
sion at the level of the joints. Both approaches are important. 
For example, in a prospective longitudinal evaluation of patients 
with RA in remission or in low disease activity state for at least 2 
months, subclinical activity observed by PD signals on US were 
able to predict subsequent disease relapse.16
Our study was focused on the evaluation of the relationship 
between US and physical examination of joints in their detec-
tion of synovitis. It is well known that synovitis detected by US 
is probably more valid in terms of face validity, and in terms of 
sensitivity rather than physical examination.10–12 In this study, 
we conﬁ rmed the higher sensitivity for US examination in 
detecting synovitis, in particular in the front region of the feet 
(table 1). However, the predictive validity of an outcome meas-
ure is probably one of the most clinically relevant issues when 
considering potential surrogate markers. Our study conﬁ rms the 
predictive validity of synovitis in terms of subsequent structural 
deterioration, but does not demonstrate the superiority of US 
in comparison with physical examination. However, our study 
suggests that both the clinical and the US examinations are rel-
evant to optimally evaluate the risk of subsequent structural 
deterioration. Such ﬁ ndings centre around the analyses of the 
subgroups of joints with either subclinical synovitis (synovitis 
detected only at US examination) or clinically detected non-US 
synovitis (synovitis detected only at clinical examination). In this 
study, we have evaluated the clinical and therapeutic parameters 
during the ﬁ rst 4 months of the study, but we were not in a posi-
tion to collect such information during the remaining 20 months 
of the study. Such lack of information might limit the interpreta-
tion of the observed data. Another potential limitation of this 
study is its relatively small sample size. The ﬁ ndings concerning 
non-US synovitis might be explained by the particular design 
of our study with experienced clinicians or research nurses to 
identify patients with synovitis who have participated at the 
training session prior to the meeting. If this explanation is the 
correct one, such ﬁ ndings reinforce the interest of a better train-
ing to any health professionals (including the rheumatologists) 
in this area.38–40 Moreover, clinical examination might have con-
sidered periarticular phenomena such as tenosynovitis in their 
Figure 3 Probability of radiological progression after a 2-year follow-up 
period with regard to the capacity of a treatment to normalise the 
joint examination in terms of synovitis. *Radiological progression = 
occurrence or worsening of erosion or joint space narrowing. **Score 
of ‘clinical’ synovitis (0 = no synovitis; 1 = doubtful synovitis; 2 = 
obvious and moderate synovitis; 3 = obvious and important synovitis. 
***Score of ultrasonography grey-scale evaluation: 0 = absence 
of synovial thickening; 1 = mild synovial thickening; 2 = moderate 
synovial thickening; 3 = marked synovial thickening. ****Score of 
ultrasonographic Power Doppler evaluation: 0 = absence of signal, no 
intra-articular fl ow; 1 = mild, one or two vessels’ signals (including 
one confl uent vessel) for small joints and two to three signals for large 
joints (including two confl uent vessels); 2 = moderate confl uent vessels 
(>grade 1) and less than 50% of normal area; 3 = marked vessels’ 
signals in more than half the synovial area.
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joint count which have not been evaluated by US examination, 
and which might help predict long-term structural progression. 
However, such ﬁ ndings (the non-superiority of US vs clini-
cal examination) might also be explained by the difﬁ culty of US 
examination justifying the current efforts to improve the training 
of ultrasonographers in this area.41–43 It might also reﬂ ect the par-
ticular US protocol employed in this study. In particular, the use 
of different US machines with relevant differences in terms of GS 
and PD performances, and also the limitation of the evaluation of 
the ﬁ ngers at the dorsal side44 might explain the non-superiority 
of US examination. Moreover, the wrist (which includes 17 dif-
ferent joints) has been evaluated in this study as a single joint.
In this study, we have also conﬁ rmed that a positive treatment 
effect (the disappearance of synovitis in the short term) is of 
beneﬁ t for the joint in terms of reducing subsequent structural 
deterioration. Our study conﬁ rms the one reported by Fukae 
et al,17 in which the researchers have split the ﬁ nger joints into 
two categories regarding the presence or absence of improve-
ment in PD-US vascularity of at least 70% after 8 weeks of 
either adalimumab or tocilizumab therapy. They showed that 
the risk of subsequent radiological progression was lower in 
the ‘responder’ joints. The conﬁ rmation of such ﬁ ndings in our 
study re-emphasises the importance of synovitis detection in 
daily practice, and also the deﬁ nition of absence of synovitis as 
one of the major targets of our therapy.7 8
Further studies are required in other sets of patients, and by 
other clinicians and ultrasonographers, in order to conﬁ rm our 
ﬁ ndings, in particular with respect to both the clinical and US 
deﬁ nitions of synovitis.
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